Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors

Huang, Ming-HungMing-HungHuangJIH-HSIANG LEEHung, Pei-ShanPei-ShanHungChih-Hsin Yang, JamesJamesChih-Hsin Yang2022-11-042022-11-042022-1126663643https://scholars.lib.ntu.edu.tw/handle/123456789/624442Although driver gene mutations have been believed to be mutually exclusive, some patients with NSCLC and concomitant EGFR mutations and EML4-ALK rearrangements have been reported. In this study, we reported a case of a patient with lung cancer who harbored both EGFR mutation and the EML4-ALK rearrangement after acquiring resistance to the EGFR tyrosine kinase inhibitor treatment. EGFR-mutant and ALK fusion proteins were detected in the same tumor cells through immunohistochemical analysis. Investigation of the molecular mechanisms of concomitant EGFR mutation and the EML4-ALK rearrangement in the same tumor cell can help discover an appropriate treatment for these patients.enALK inhibitor; EGFR; EGFR-TKI; EML4-ALK; Lung cancer[SDGs]SDG3Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitorsjournal article10.1016/j.jtocrr.2022.100405363251532-s2.0-85140472771https://api.elsevier.com/content/abstract/scopus_id/85140472771